Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases.

Yeniad B, Ayranci O, Tuncer S, Kir N, Ovali T, Tugal-Tutkun I, Akarcay K.

Eur J Ophthalmol. 2011 Mar-Apr;21(2):156-61.

PMID:
20658459
2.

Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American Collaborative Retina Group (PACORES).

Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7. Epub 2007 Aug 3.

PMID:
17674014
3.

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.

Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, Alezzandrini AA, Díaz-Llopis MJ.

Retina. 2010 Jul-Aug;30(7):1002-11. doi: 10.1097/IAE.0b013e3181cea68d.

PMID:
20616679
4.

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.

Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, Alezzandrini AA, Díaz-Llopis MJ.

Retina. 2009 Nov-Dec;29(10):1396-403. doi: 10.1097/IAE.0b013e3181bcef53.

PMID:
19898177
5.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group.

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
6.

Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.

Blaha GR, Brooks NO, Mackel CE, Pani A, Stewart AP, Price LL, Barouch FC, Chang J, Marx JL.

Retina. 2015 Mar;35(3):577-81. doi: 10.1097/IAE.0000000000000334.

PMID:
25158942
7.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
8.

Bilateral simultaneous intravitreal injections in the office setting.

Bakri SJ, Risco M, Edwards AO, Pulido JS.

Am J Ophthalmol. 2009 Jul;148(1):66-9.e1. doi: 10.1016/j.ajo.2009.02.013. Epub 2009 Apr 29.

PMID:
19403114
9.

Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.

Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS.

Retina. 2008 Oct;28(8):1151-8. doi: 10.1097/IAE.0b013e31817e100f.

PMID:
18685542
10.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
11.

[Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].

Jonas JB, Kreissig I, Kamppeter B, Degenring RF.

Ophthalmologe. 2004 Feb;101(2):113-20. Review. German.

PMID:
14991306
12.

Paracentesis before intravitreal injection of bevacizumab.

Tsui YP, Chiang CC, Tsai YY.

Can J Ophthalmol. 2008 Apr;43(2):239; author reply 239-40. doi: 10.3129/i08-033. No abstract available.

PMID:
18347632
13.

Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema.

Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK.

Doc Ophthalmol. 2008 Mar;116(2):129-35. Epub 2007 Oct 25.

PMID:
17960440
14.

Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab.

Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U.

Retina. 2006 Oct;26(8):877-81.

PMID:
17031286
15.

[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].

Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.

J Fr Ophtalmol. 2011 Jun;34(6):376-81. doi: 10.1016/j.jfo.2011.03.004. Epub 2011 May 7. French.

16.

Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.

Tao Y, Jonas JB.

Retina. 2010 Oct;30(9):1426-31. doi: 10.1097/IAE.0b013e3181d5e964.

PMID:
20539255
17.

Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.

Yasuda S, Kondo M, Kachi S, Ito Y, Terui T, Ueno S, Terasaki H.

Retina. 2011 Jun;31(6):1075-82. doi: 10.1097/IAE.0b013e318206cf4b.

PMID:
21478810
18.

Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.

Rensch F, Jonas JB, Spandau UH.

Acta Ophthalmol. 2009 Feb;87(1):77-81. doi: 10.1111/j.1755-3768.2008.01313.x. Epub 2008 Oct 17.

19.

Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion.

Astam N, Batioğlu F, Ozmert E.

Int Ophthalmol. 2009 Oct;29(5):343-8. doi: 10.1007/s10792-008-9242-2. Epub 2008 Jun 14.

PMID:
18553061
20.

Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.

Mayer WJ, Remy M, Wolf A, Kook D, Kampik A, Ulbig M, Reznicek L, Haritoglou C.

Ophthalmologica. 2012;228(2):110-6. doi: 10.1159/000338732. Epub 2012 Jun 23.

PMID:
22739239

Supplemental Content

Support Center